and Food and Drug Administration (FDA), as well as the Department of Labor and Federal Trade Commission (FTC) over the next year. These directives set the stage for a sustained focus on drug ...

Beyond drug discovery, Eisai is committed to developing the appropriate infrastructure for AD treatment, including blood biomarkers (BBMs) for diagnosis. A new era of AD AD is a progressive ...